The Financial Post reports in its Saturday, May 23, edition that telehealth provider Hims & Hers Health announced Thursday the availability of generic semaglutide through its platform. The Post's Denise Pagliniwan writes that with Health Canada's approval of the first two generic injection semaglutide, the medication popularized by Novo Nordisk's Ozempic, Canadians can now access a more affordable version of the drug prescribed in the treatment of Type 2 diabetes but widely used off-label as an anti-obesity medication. Hims & Hers has started offering eligible customers personalized treatment plans starting at $149/month, which would include the medication. "Generic medication will be more affordable than other options, and I think that will be a particularly attractive opportunity for Canadians," said Austin Kouri, general manager of Hims & Hers Canada. "This is obviously a little bit of an unprecedented environment, with Canada being one of the first to bring generics in the market." Canada is the first in the G7 to have an approved generic version of semaglutide, following Health Canada's approval of one made by Dr. Reddy's Laboratories on April 28 and a second one from Apotex on May 1.